Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer

NCT01710592 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT01710592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01710592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
Not reported
Enrollment
35 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gastro oesophageal cancer